Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study-Reference-Cited by-同舟云学术

Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study

Published:2022-04-16 Issue:2 Volume:116 Page:215-227
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Edahiro Yoko,Ohishi Kohshi,Gotoh Akihiko,Takenaka Katsuto,Shibayama Hirohiko,Shimizu Takayuki,Usuki Kensuke,Shimoda Kazuya,Ito Masafumi,VanWart Scott A.,Zagrijtschuk Oleh,Qin Albert,Kawase Hiroaki,Miyachi Narihisa,Sato Toshiaki,Komatsu Norio,Kirito Keita

Funder

PharmaEssentia Japan K.K.

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12185-022-03341-9.pdf

Reference49 articles.

1. Benevolo G, Vassallo F, Urbino I, Giai V. Polycythemia Vera (PV): update on emerging treatment options. Ther Clin Risk Manag. 2021;17:209–21.

2. Kralovics R, Passamonti F, Buser AS, Teo S, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–90.

3. Fowles JS, How J, Allen MJ, Oh ST. Young versus old age at diagnosis confers distinct genomic profiles in patients with polycythemia vera. Leukemia. 2019;33:1522–6.